½ÃÀ庸°í¼­
»óǰÄÚµå
1735552

¼¼°èÀÇ º¹¼ö ½ÃÀå : Áö¿ª ¹× ±¹°¡º° ºÐ¼®°ú ¿¹Ãø(2025-2035³â)

Ascites Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: BIS Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 1-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

º¹¼ö ½ÃÀåÀº ´Ù¾çÇÑ ¿äÀο¡ ÀÇÇØ Å« ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ¼ºÀå ¿äÀÎ Áß Çϳª´Â °£°æº¯ÁõÀ» ºñ·ÔÇÑ °£ Áúȯ°ú °£¾Ï, ³­¼Ò¾Ï, ÃéÀå¾Ï µîÀÇ ¾Ï ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. À̵é ÁúȯÀº ¸ðµÎ º¹¼öÀÇ ÁÖ¿ä ¿øÀÎÀ̸ç, Àü ¼¼°èÀûÀ¸·Î ÀÌ·¯ÇÑ Áúȯ Áõ°¡´Â Áø´Ü µµ±¸¿Í Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. »ýȰ½À°üº´, ¾ËÄÚ¿Ã ¼Òºñ, °£¿° °¨¿° Áõ°¡µµ ÀÌ·¯ÇÑ Ãß¼¼¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖÀ¸¸ç, ±× °á°ú º¹¼ö ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ ÃÊÀ½ÆÄ, CT ½ºÄµ, õÀÚ ¾× ºÐ¼® µî ¿µ»ó Áø´Ü ±â¼úÀÇ ¹ßÀü°ú °³¼±µµ ½ÃÀå ¼ºÀåÀÇ Å« ¿äÀÎÀÔ´Ï´Ù. Á¶±â ¹ß°ß°ú Á¤È®ÇÑ Áø´ÜÀÌ °¡´ÉÇØÁü¿¡ µû¶ó Àû½Ã¿¡ °³ÀÔÀÌ °¡´ÉÇØÁ® Ä¡·á ¼ºÀûÀÌ Çâ»óµÉ ¼ö ÀÖ½À´Ï´Ù. ºñħ½ÀÀûÀÌ°í ¹Î°¨ÇÑ Áø´Ü °Ë»çÀÇ º¸±ÞÀº º¹¼öÀÇ Á¶±â Áø´Ü °¡´É¼ºÀ» ³ôÀ̰í, ÀÌ¿¡ µû¶ó Ä¡·á ¹× °ü¸®¿¡ ´ëÇÑ ¼ö¿äµµ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

±×·¯³ª ½ÃÀåÀÌ °è¼Ó ¼ºÀåÇϰí ÀÖ´Â ¹Ý¸é, ¸î °¡Áö ¹®Á¦Á¡µµ Á¸ÀçÇÕ´Ï´Ù. ±× Áß °¡Àå Å« °úÁ¦ Áß Çϳª´Â °£À̽Ä, È­Çпä¹ý, ½Å¾à µî °íµµÀÇ Ä¡·á¹ý¿¡ ´ëÇÑ ³ôÀº Ä¡·áºñÀÔ´Ï´Ù. ƯÈ÷ °³¹ßµµ»ó±¹¿¡¼­´Â ÀÇ·á ÀÎÇÁ¶ó°¡ ¹ÌºñÇÏ°í °í°¡ Ä¡·á¿¡ ´ëÇÑ º¸Çè Àû¿ë ¹üÀ§°¡ Á¦ÇÑÀûÀ̱⠶§¹®¿¡ ÀÌ·¯ÇÑ ºñ¿ëÀÌ Ä¡·áÀÇ Å« À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °æÁ¦Àû ºÎ´ãÀº ¸¹Àº ȯÀڵ鿡°Ô ÇÊ¿äÇÑ Ä¡·á¿¡ ´ëÇÑ Á¢±ÙÀ» ¾î·Æ°Ô ÇÏ°í ½ÃÀå ¼ºÀåÀ» Á¦ÇÑÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, Ä¡·á·Î ÀÎÇÑ ºÎÀÛ¿ë°ú ÇÕº´ÁõÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ¾ïÁ¦Çϰí ÀÖ½À´Ï´Ù. ÀÌ´¢Á¦ ¹× º¹°­ õÀÚ¸¦ Æ÷ÇÔÇÑ ÀϺΠº¹¼ö Ä¡·á´Â ÀüÇØÁú ºÒ±ÕÇü, °¨¿°, ÀúÇ÷¾Ð°ú °°Àº ÇÕº´Áõ ¹× ºÎÀÛ¿ëÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀáÀçÀû À§ÇèÀº ȯÀÚµéÀÌ Ä¡·á¸¦ ¹Þ°Å³ª ó¹æµÈ ¿ä¹ýÀ» ÁؼöÇÏ´Â °ÍÀ» ÁÖÀúÇÏ°Ô ¸¸µé ¼ö ÀÖÀ¸¸ç, °á°úÀûÀ¸·Î ÀÌ·¯ÇÑ °³ÀÔ¿¡ ´ëÇÑ Àü¹ÝÀûÀÎ ¼ö¿ä¸¦ Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º¹°­ õÀÚ¸¦ ¹Ýº¹ÇØ¾ß ÇÏ´Â µî ÀϺΠġ·á´Â ħ½ÀÀû ¼º°ÝÀ» ¶ì°í ÀÖ¾î ȯÀÚ¿¡°Ô ºÒÆíÇÔÀ» ÁÙ ¼ö ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¼±Åÿ¡ ´ëÇÑ È¯ÀÚµéÀÇ °ÅºÎ°¨À» °¨¼Ò½Ãų ¼ö ÀÖ½À´Ï´Ù.

¼¼°èÀÇ º¹¼ö ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ÁÖ¿ä µ¿Çâ, ½ÃÀå ¿µÇâ¿äÀÎ ºÐ¼®, ¹ý ¹× ±ÔÁ¦ ȯ°æ, ÀÓ»ó½ÃÇè µ¿Çâ, ½ÃÀå ±Ô¸ð ÃßÀÌ ¹× ¿¹Ãø, °¢Á¾ ºÎ¹®º°/Áö¿ªº°/ÁÖ¿ä ±¹°¡º° »ó¼¼ ºÐ¼®, °æÀï ±¸µµ, ÁÖ¿ä ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

ÁÖ¿ä ¿ä¾à

Á¦1Àå ¼¼°èÀÇ º¹¼ö ½ÃÀå : ¾÷°è Àü¸Á

  • ½ÃÀå µ¿Çâ
  • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
  • º¹¼ö ¿ªÇÐ
  • ÀÓ»ó½ÃÇè ºÐ¼®
  • ½ÃÀå ¿ªÇÐ
    • ¿µÇ⠺м®
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
    • ½ÃÀå ±âȸ

Á¦2Àå ¼¼°èÀÇ º¹¼ö ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÁÖ¿ä Á¶»ç °á°ú
    • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø

Á¦3Àå ¼¼°èÀÇ º¹¼ö ½ÃÀå : °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

  • ÁÖ¿ä °³¹ß°ú Àü·«
    • ÀμöÇÕº´(M&A)
    • ½Ã³ÊÁö Ȱµ¿
    • »ç¾÷ È®´ë¿Í ÀÚ±ÝÁ¶´Þ
    • Á¦Ç° ¹ß¸Å¿Í ½ÂÀÎ
    • ±âŸ
  • ±â¾÷ °³¿ä
    • Ocelot Bio
    • PharmaIN
    • Grifols Therapeutics LLC.
    • Regeneron Pharmaceuticals.
    • BioVie Inc

Á¦4Àå Á¶»ç ¹æ¹ý

LSH 25.06.12

Global Ascites Market, Analysis and Forecast: 2025-2035

Ascites is the abnormal accumulation of fluid in the peritoneal cavity, which is the space surrounding the organs in the abdomen. This condition can cause the abdomen to become distended or swollen and is often a sign of an underlying medical issue. It is typically associated with liver diseases, particularly cirrhosis, but can also result from cancer, heart failure, kidney disease, or infections.

The ascites market is witnessing substantial growth, driven by a range of key factors. One of the primary drivers for the ascites market is the rising prevalence of liver diseases, particularly cirrhosis, as well as various forms of cancer, such as liver, ovarian, and pancreatic cancer. As these diseases are among the leading causes of ascites, their increasing incidence globally is driving the demand for diagnostic tools and treatment options. The global rise in lifestyle diseases, alcohol consumption, and hepatitis infections has contributed to this increase, which in turn propels the growth of the ascites market.

Furthermore, the development and improvement of diagnostic technologies, including imaging techniques like ultrasound, CT scans, and the use of paracentesis for fluid analysis, are major drivers for the ascites market. Early detection and accurate diagnosis allow for timely intervention, improving treatment outcomes. The availability of non-invasive and highly sensitive diagnostic tests increases the likelihood of diagnosing ascites in its early stages, expanding the demand for related treatment and management options.

Despite the positive growth trajectory, several challenges continue to impact the global ascites market. One of the primary challenges is the high cost of treatments, particularly for advanced interventions such as liver transplants, chemotherapy, and some novel drug therapies. These costs can be a significant barrier to access, especially in developing regions where healthcare infrastructure may be limited, and insurance coverage for expensive treatments may not be available. This high cost can restrict the market growth, as many patients may not be able to afford the necessary care.

Moreover, side effects and complications of treatment further restrict the market growth. Several treatments for ascites, including diuretics and paracentesis, can lead to complications or side effects, such as electrolyte imbalances, infections, or low blood pressure. These potential risks may deter patients from seeking treatment or adhering to prescribed regimens, thus limiting the overall demand for these interventions. Additionally, the invasive nature of some treatments, such as the need for repeated paracentesis, can be uncomfortable for patients and may result in decreased willingness to pursue these options.

Leading players in the global ascites market, such as Ocelot Bio, Regeneron Pharmaceuticals, and BioVie Inc., are continuously focusing on several strategies to maintain their competitive edge and drive growth. These strategies include continuous technological innovation, such as the development of more advanced and efficient treatment options, mapping systems, and imaging technologies. These companies aim to enhance the safety and efficacy of ascites treatment options.

The competitive landscape of the global ascites market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as Asia-Pacific and Latin America. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the ascites market will continue to evolve, fostering new opportunities for both established and emerging companies.

As the ascites market continues to evolve, several emerging trends are expected to significantly influence its future trajectory. The aging global population is another significant factor driving the ascites market. Older adults are more prone to liver diseases, heart failure, and cancer, all of which are major risk factors for ascites. As the number of elderly individuals increases, the prevalence of ascites is expected to rise, further driving the demand for effective treatments and management strategies.

In conclusion, the global ascites market is expected to see steady growth, driven by the increasing prevalence of underlying conditions such as liver diseases and cancers, as well as advancements in diagnostic and therapeutic options. Continued research and innovation in targeted treatments, along with a growing focus on early detection, will be key to improving patient outcomes and reducing the burden of ascites on healthcare systems. As stakeholders, including pharmaceutical companies, healthcare providers, and researchers, continue to work toward better management strategies, the market will evolve to offer more effective solutions, ultimately enhancing the quality of life for patients and addressing the ongoing challenges posed by this condition.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Ascites Markets: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiology of Ascites
  • 1.5 Clinical Trial Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Ascites Market, by Region, $Million, 2023-2035

  • 2.1 North America
    • 2.1.1 Key Findings
    • 2.1.2 Market Dynamics
    • 2.1.3 Market Sizing and Forecast
      • 2.1.3.1 North America Ascites Market, by Country
        • 2.1.3.1.1 U.S.
  • 2.2 Europe
    • 2.2.1 Key Findings
    • 2.2.2 Market Dynamics
    • 2.2.3 Market Sizing and Forecast
      • 2.2.3.1 Europe Ascites Market, by Country
        • 2.2.3.1.1 Germany
        • 2.2.3.1.2 U.K.
        • 2.2.3.1.3 France
        • 2.2.3.1.4 Italy
        • 2.2.3.1.5 Spain
  • 2.3 Asia Pacific
    • 2.3.1 Key Findings
    • 2.3.2 Market Dynamics
    • 2.3.3 Market Sizing and Forecast
      • 2.3.3.1 Asia Pacific Ascites Market, by Country
        • 2.3.3.1.1 Japan

3. Global Ascites Market: Competitive Landscape and Company Profiles

  • 3.1 Key Development and Strategies
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Synergistic Activities
    • 3.1.3 Business Expansions and Funding
    • 3.1.4 Product Launches and Approvals
    • 3.1.5 Other Activities
  • 3.2 Company Profiles
    • 3.2.1 Ocelot Bio
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Target Customers/End-Users
      • 3.2.1.4 Key Personnel
      • 3.2.1.5 Analyst View
    • 3.2.2 PharmaIN
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Target Customers/End-Users
      • 3.2.2.4 Key Personnel
      • 3.2.2.5 Analyst View
    • 3.2.3 Grifols Therapeutics LLC.
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Target Customers/End-Users
      • 3.2.3.4 Key Personnel
      • 3.2.3.5 Analyst View
    • 3.2.4 Regeneron Pharmaceuticals.
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Target Customers/End-Users
      • 3.2.4.4 Key Personnel
      • 3.2.4.5 Analyst View
    • 3.2.5 BioVie Inc
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Target Customers/End-Users
      • 3.2.5.4 Key Personnel
      • 3.2.5.5 Analyst View

4. Research Methodology

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦